ucsf banner
Left Navigation Pane Image
Department of Clinical Pharmacy

Faculty & Staff

B
Bero, Lisa Anne, Ph.D. Bero, Lisa Anne, Ph.D.

  • Current Title(s):
    • Co-Director, San Francisco Branch United States Cochrane Center
    • Professor, Department of Clinical Pharmacy, School of Pharmacy
    • Professor, Institute for Health Policy Studies, School of Medicine
    • Vice Chair – Research, Department of Clinical Pharmacy
  • First Year on UCSF Faculty: 1987
  • Education:
    • Bachelor of Science, Physiology/Philosophy, Michigan State University, 1980
    • Doctor of Philosophy, Pharmacology and Toxicology, Duke University, 1987
  • Specialty:
    • Academic - industry relations
    • Pharmaceutical Outcomes Assessment
    • Pharmacology
    • Tobacco Control Policy
    • Translation of research into policy
  • Special Appointments/Fellowships/Awards:
    • Member of Study Session Drug Protocol Review Committee for Agenzia Italiana del
    • Member of the Advisory Committee on Health Research of the Pan American Health

San Francisco, Laurel Heights  Box 0613, 3333 California Street, Suite 420, San Francisco, CA 94118
Phone: (415) 476-1067,  Fax: (415) 502-0792,  Email: berol@pharmacy.ucsf.edu


Professional Biography
Lisa A. Bero, PhD is a Professor, Department of Clinical Pharmacy and Faculty member, Institute for Health Policy Studies, University of California, San Francisco. She is a pharmacologist with primary interests in how clinical and basic sciences are translated into clinical practice and health policy. She has developed and validated methods for assessing bias in research and scientific publication and measures influences on the quality of research, including university-industry relations. Dr. Bero has also conducted analyses to examine the dissemination and policy implications of research evidence. This includes examining how evidence is used by regulators and legislators, and how it is covered in the lay press.

Dr. Bero teaches a core course on critical appraisal of the medical literature for pharmacy students and lectures across campus on topics including meta-analysis, research translation and tobacco control policy. She has designed and implemented a curriculum that examines the influences of pharmaceutical industry marketing.

Dr. Bero’s international activities include advisor to the World Health Organization Drug Action Programme as a member of the WHO Essential Medicines Committee and member of the Pan American Health Organization Advisory Committee on Health Research. She is Co-Director of the San Francisco Branch of the United States Cochrane Center. She is a senior editor for Tobacco Control and editor for the Cochrane Effective Practice and Organization of Care Group -- an international group of researchers conducting meta-analyses of the literature on interventions aimed at getting research into practice. She is an elected member of the Cochrane Collaboration Steering Group and serves on several national and international committees related to conflicts of interest and research, such as the Institute of Medicine Committee on Conflict of Interest in Medical Research, Education and Practice.


Selected Peer-reviewed Publications

  • B Shamasunder, & L Bero. Financial Ties and Conflicts of Interest Between Pharmaceutical and Tobacco Companies. Journal of the American Medical Association, 288: 738-744 (2002).
  • Jewell, C, and Bero, L. Developing good taste in evidence: Facilitators and hindrances to evidence-informed health policy making in state government, The Milbank Quarterly, 2008 Jun; 86(2):177-208.
  • Boyd EA, Cho MK, & Bero LA. Financial Conflict-of-Interest Policies in Clinical Research: Issues for Clinical Investigators. Academic Medicine, 78: 769-774 (2003).
  • Apollonio, D., and Bero, L. The Creation of Industry Front Groups: The Tobacco Industry and “Get Government Off Our Back”, American Journal of Public Health, 97: 419-427 (2007).
  • Bero, LA, and Kuhn, CM. Catecholaminergic regulation of opiate-stimulated growth hormone secretion in the developing rat, The Journal of Pharmacology and Experimental Therapeutics, 1986; 237: 137-142.
  • Boyd, E.A., & Bero, L.A. Assessing Faculty Financial Relationships with Industry: A Case Study. Journal of the American Medical Association, 284(17): 2209-2214 (2000).
  • Bero, LA, DE Barnes, P Hanauer, J Slade, SA Glantz. Lawyer Control of the Tobacco Industry''s External Research Program: The Brown and Williamson Documents. Journal of the American Medical Association, 274: 241-247 (1995).
  • Bero, L. Big Pharma (The Play). PLOS Biology, 5: 0701-0702 (2007).
  • Bero, L., Roy, SA, and Lee, NM. Identification of endogenous opioid receptor components in rat brain using a monoclonal antibody, Molecular Pharmacology, 1988; 34: 614-620.
  • Devine, E., Beney, J., & Bero, L. Equity, Accountability, Transparency: Implementation of the Contributorship Concept in a Multi-site Study. American Journal of Pharmaceutical Education, 69: 455-459 (2005).
  • Nguyen, NT., Cook, DM., & Bero, LA. The Decision-Making Process of US Food and Drug Administration Advisory Committees on Switches from Prescription to Over-the Counter Status: A Comparative Case Study. Clinical Therapeutics, 28: 1231-1243 (2006).
  • Malone, R.E., Boyd, E., Bero, L.A. Science in the News: Journalists’ Constructions of Passive Smoking as a Social Problem. Social Studies of Science, 30(5): 713-735 (2000).
  • Nkansah, N, Nguyen, T, Iraninezhad, H and Bero, L. Randomized trials assessing calcium supplementation in healthy children: Relationship between industry sponsorship and study outcomes, Public Health Nutrition, 2009; doi:10.1017/S136898000900487X.
  • Malone, R. E., Wenger, L. D. & Bero, L. A. Making the Cigar News. Tobacco Control, 9: 435-437 (2000).
  • Apollonio, DE, P Lopipero, and L. Bero. Participation and Argument in Legislative Debate on Statewide Smoking Restrictions. Health Research and Policy Systems, 5: 1-11 doi:10.1186/1478-4505-5-12 (2007).
  • Finley PR., Rens HR., Pont JT., Gess SL., Louie C., Bull SA., Lee JY., Bero LA. Impact of A Collaborative Care Model on Depression in A Primary Care Setting: A Randomized Controlled Trial. Pharmacotherapy, 23: 1175-1185 (2003).
  • Baba, A., Cook, D., McGarity, T., Bero, L. Legislating “Sound Science”: Role of the Tobacco Industry. American Journal of Public Health, 95: S20-S27 (2005).
  • Bero, LA, and Kuhn, CM. Differential ontogeny of opioid, dopaminergic and serotonergic regulation of Prolactin Secretion, The Journal of Pharmacology and Experimental Therapeutics, 1987; 240: 825-830.
  • Barnes, D and L Bero. Industry-Funded Research and Conflict of Interest: An Analysis of Research Sponsored by the Tobacco Industry through the Center for Indoor Air Research. Journal of Health Politics,Policy and Law, 21 (3): 515-542 (1996).
  • Jewell C., & Bero, L. Public Participation and Claimsmaking: Evidence Utilization and Divergent Policy Frames in California’s Ergonomics Rulemaking. Journal of Public Administration Research and Theory, doi: 10.1093/jopart/mul023 (December 2006).
  • Prochaska, J., Hall, S., and Bero, L. Tobacco use Among Individuals with Schizophrenia: What Role has the Tobacco Industry Played? Schizophrenia Bulletin, doi:10.1093/schbul/sbm117 (2007).
  • Bero, LA., Oostvogel, F., Bacchetti, P., & Lee, K. Factors Associated with Findings of Published Trials of Drug-Drug Comparisons: Why Some Statins Appear More Efficacious than Others. PLOS Medicine, 4: 0001-0010 (2007).
  • Montini, T, and Bero, L. Implementation of a workplace smoking ban in bars: The limits of local discretion, BMC Public Health, 2008, 8:402 doi:10.1186/1471-2458-8-402.
  • L.A. Bero, H.L. Lipton, and J.A. Bird. Characterization of Geriatric Drug-Related Hospital Readmissions. Med. Care, 29: 989-1003 (1991).
  • Bero, L.A. Clinical Trial Registration at Tobacco Control. Tobacco Control, 15: 417-418 (2006).
  • Bero, L.A., Montini, T., Bryan-Jones, K., & Manguarian, C. Science in Regulatory Policy Making: Case Studies in the Development of Workplace Smoking Restrictions. Tobacco Control,10(4): 329-336 (2001).
  • Bryan-Jones K, & Bero L. Tobacco Industry Efforts to Defeat the Occupational Safety and Health Administration Indoor Air Quality Rule. American Journal of Public Health, 93: 585-592 (2003).
  • Wenger, L. D., Malone, R. E. & Bero, L. A. The Cigar Revival and the Popular Press: A Content Analysis 1987-1997. American Journal of Public Health, 91(2): 288-291 (2001).
  • Bero, LA and D Rennie. Influences on the Quality of Published Drug Studies. Int J Technol Assessment in Health Care, 12 (2): 209-237 (1996).
  • Cho, MK, LA Bero. Instruments for Assessing the Quality of Drug Studies Published in the Medical Literature. Journal of the American Medical Association, 272: 101-104 (1994).
  • SA Glantz, DE Barnes, L A Bero, P Hanauer, J Slade. Looking Through a Keyhole at the Tobacco Industry: The Brown and Williamson Documents. Journal of the American Medical Association, 274: 219-224 (1995).
  • Odierna, D and Bero, L. Systematic reviews reveal an unrepresentative evidence base for the development of drug formularies for poor and nonwhite populations, J Clin Epidemiol, in press.
  • Cook, D., and Bero, L. Identifying Carcinogens: The Tobacco Industry and Regulatory Politics in the United States. Int J of Health Services, 36: 747-766 (2006).
  • Glaser, BE., & Bero, LA. Attitudes of Academic and Clinical Researchers Toward Financial Ties in Research: A Systematic Review. Science and Engineering Ethics, 11: 553-573 (2005).
  • Rising, K, Bacchetti, P, and Bero, L. Reporting bias in drug trials submitted to the Food and Drug Administration: A review of publication and presentation, PLoS Medicine, 2008; 5 (11) e217 doi:10.1371/journal.pmed.0050217.
  • Bero L. Implications of the Tobacco Industry Documents for Public Health and Policy. Annu. Rev. Public Health, 24: 267-288 (2003).
  • White J, & Bero L. Public Health Under Attack: The American Stop Smoking Intervention Study (ASSIST) and the Tobacco Industry. American Journal of Public Health, 94: 240-250 (2004).
  • Bero, LA, and Kuhn, CM. Role of serotonin in opiate-induced prolactin secretion and aantinociception in the developing rat, The Journal of Pharmacology and Experimental Therapeutics, 1987; 240: 831-836.
  • Kilts, CD, and Bero, LA. Quantitative determination of 5-hydroxytryptophan in dissected brain regions by on-line trace enrichment HPLC with electrochemical detection, Life Sciences, 1984; 35: 87-95.
  • Stryer, D and L Bero. Characteristics of Materials Distributed by Drug Companies. Journal of General Internal Medicine, 11: 575-583 (1996).
  • Dunsby, J., & Bero, L. A Nicotine Delivery Device Without the Nicotine? Tobacco Industry Development of Low Nicotine Cigarettes. Tobacco Control, 13: 362-369 (2004).
  • Bero, LA., Glantz, S., & Hong, M-K. The Limits of Competing Interest Disclosures. Tobacco Control, 14: 118-126 (2005).
  • Cho, M and L Bero. The Quality of Drug Articles Published in Symposium Proceedings. Annals of Internal Medicine, 124: 485-489 (1996).
  • Hanauer, P, J Slade, DE Barnes, LA Bero, SA Glantz. Lawyer Control of Internal Scientific Research to Protect Against Products Liability Lawsuits: The Brown and Williamson Documents. Journal of the American Medical Association, 274: 234-240 (1995).
  • L.A. Bero, A. Galbraith, and D. Rennie. The Publication of Sponsored Symposiums in Medical Journals. New England Journal of Medicine, 327: 1135-1140 (1992).
  • Cook, D., Tong, E., Glantz, S., & Bero, L. The Power of Paperwork: How Philip Morris Neutralized the Medical Code for Secondhand Smoke. Health Affairs, 24: 994-1004 (2005).
  • Montini, T, George, A, Martin-Mollard, M, and Bero, L. The role of public participation in public health initiatives: An analysis of WHO’s framework convention on tobacco control, Global Public Health, in press.
  • Grimshaw, J., Shirran, L., Thomas, R., Mowatt, G., Fraser, C., Bero, L., Grilli, R., Harvey, E., Oxman, A., & O’Brien, MA. Changing Provider Behavior: An Overview of Systematic Reviews of Intervention. Medical Care, 39(8): II-2-II-45 (2001).
  • Bero L, Freemantle N, Grilli R, Grimshaw J, Harvey E, Oxman AD, Thomson MA, on behalf of the Cochrane Collaboration on Effective Professional Practice. Closing the Gap Between Research and Practice: An Overview of Systematic Reviews of Interventions to Promote Implementation of Research Findings by Health Care Professionals. British Medical Journal, 317: 465-468 (1998).
  • Kummerfeldt, C, Barnoya, J, and Bero, L. Philip Morris involvement in the development of an air quality laboratory in El Salvador, Tobacco Control, 2009; 18 (1) doi: 10.1136/tc.2008.026989.
  • Phillips, KA and L Bero. Improving the Use of Information in Medical Effectiveness and Quality Research. International Journal for Quality in Health Care, 8 (1): 21-30 (1996).
  • Lexchin J, Bero L, Djulbegovic B, & Clark O. Pharmaceutical Industry Sponsorship and Research Outcome and Quality: Systematic Review. British Medical Journal, 326: 1167-1170 (2003).
  • Moynihan, R., Bero, L. A., Ross-Degnan, D., Henry, D., Lee, K., Watkins, J., Mah, C. & Soumerai, S.B. Coverage By the News Media of the Benefits and Risks of Medications. NEJM, 342: 1645-1650 (2000).
  • Boyd, EA., & Bero, LA. Improving the Use of Research Evidence in Guideline Development: 4. Managing Conflicts of Interests. Health Research Policy and Systems, 4: (online December 1, 2006).
  • T Montini, C Mangurian, & L Bero. Assessing the Evidence Submitted in the Development of a Workplace Smoking Regulation: The case of Maryland. Public Health Reports, 117: 291-298 (2002).
  • Lee, K., Boyd, E., Holroyd-Leduc, J., Bacchetti, P., and Bero, L. Predictors of Publication: Characteristics of Submitted Manuscripts Associated With Acceptance at Major Biomedical Journals. Medical Journal of Australia, 184: 621-626 (2006).
  • Bero, LA. Managing Financial Conflicts of Interests in Research. Journal of the American College of Dentists, 72: 4-9 (2005).
  • G Mowatt, L Shirran, J Grimshaw, D Rennie, A Flanagin, V Yank, G MacLennan, P Gotzsche, and L Bero. Prevalence of Honorary and Ghost Authorship in Cochrane Reviews. Journal of the American Medical Association, 287: 2769-2771 (2002).
  • Cook, D, and Bero, L. The politics of smoking in federal buildings: An executive order case study, American Journal of Public Health, in press.
  • R Malone, L Wenger, and L Bero. High School Journalists’ Perspectives on Tobacco. Journal of Health Communication, 7 (2): 139-156 (2002).
  • Bero, LA, SA Glantz, D Rennie. Publication Bias and Public Health Policy on Environmental Tobacco Smoke. Journal of the American Medical Association, 272: 133-136 (1994).
  • Barnes, D. and L. Bero. Scientific Quality of Original Research Articles on Environmental Tobacco Smoke. Tobacco Control, 6:19-26 (1997).
  • Steinman, MA., Harper, GM., Chren, MM., Landefeld, CS., & Bero, LA. Characteristics and Impact of Drug Detailing for Gabapentin. PLOS Medicine, 4: 0743-0751 (2007).
  • Barnes, DE; Bero, LA. Why Review Articles on the Health Effects of Passive Smoking Reach Different Conclusions. Journal of the American Medical Association, 279(19):1566-70 (1998).
  • Malone, R.E. & Bero, L.A. Cigars, Youth, and the Internet Link. American Journal of Public Health, 90(5): 790-792 (2000).
  • L.A. Bero, A. Galbraith, and D. Rennie. Sponsored Symposia on Environmental Tobacco Smoke. Journal of the American Medical Association, 271: 612-617 (1994).
  • Akera, T, Ng, YC, Shieh, IS, and Bero, L. Brody TM, & Braselton WC. Effects of potassium on the interaction between cardiac glycosides and Na,K-ATPase, European Journal of Pharmacology, 1985; 111: 147-158.
  • SA Glantz, J Slade, L Bero, P Hanauer, D Barnes. The Cigarette Papers. Berkeley, Ca: UC Press, (1996).
  • Slade, J, LA Bero, P Hanauer, DE Barnes, SA Glantz. Nicotine and Addiction: The Brown and Williamson Documents. Journal of the American Medical Association, 274: 225-233 (1995).
  • Yank, V. Rennie, D, and Bero, L. Financial Ties and Concordance Between Results and Conclusions in Meta-analyses: Retrospective Cohort. BMJ, 335: 1202-1205 (2007).
  • Hong, M-K., and Bero, L. Tobacco Industry Sponsorship of a Book and Conflict of Interest. Addiction, 101: 1202-1211 (2006).
  • Bero, LA, Lurie, SN, and Kuhn, CM. Early ontogeny of kappa-opioid receptor regulation of prolactin secretion in the rat, Developmental Brain Research, 1987; 465: 189-196.
  • White, J, Bandura, A and Bero, L. Moral disengagement in the corporate world, Accountability in Research, 2009; 16: (1) 41 — 74 doi: 10.1080/08989620802689847.
  • Cook, DM, Boyd, EA., Grossman, C., and Bero, L. Reporting Science and Conflicts of Interest in the Lay Press. PLOS, 2: e1266. doi:10.1371/journal.pone.0001266 (2007).
  • Cook, D, Boyd, E, Grossmann, C, and Bero, L. Journalists and conflicts of interest in science: Beliefs and practices, Ethics in Science and Environmental Politics, in press.
  • Bero, L.A. Commentary: Educational Advertisements I Haven''t Seen One Yet!. The Western Journal of Medicine, 174 (6): 395 (2001).
  • Wenger, L., Malone, R., George, A., & Bero, L. Cigar Magazines: Using Tobacco to Sell A Lifestyle. Tobacco Control, 10(3): 279-284 (2001).
  • K Lee, M Schotland, P Bacchetti, and L Bero. Association of Journal Quality Indicators With Methodological Quality of Clinical Research Articles. Journal of the American Medical Association, 287: 2805-2808 (2002).
  • Bero, L.A., & Schotland, M.S. Evaluating Public Commentary and Scientific Evidence Submitted in the Development of A Risk Assessment. Risk Analysis, 22(1): 131-140 (2002).
  • Roth A, Dunsby J, & Bero L. Framing Processes in Public Commentary on U.S. Federal Tobacco Control Regulation. Social Studies of Science, 33: 7-44 (2003).
  • Malone RE, & Bero LA. Chasing the Dollar: Why Scientists Should Decline Tobacco Industry Funding. Journal of Epidemiology and Community Health, 57: 546-548 (2003).
  • Bero, L. & Shojania, K. Taking Advantage of the Explosion of Systematic Reviews: An Efficient Medline Search Strategy. Effective Clinical Practice, 4: 157-162 (2001).
  • Glantz, SA, LA Bero. Inappropriate and Appropriate Selection of "Peers" in Grant Review. Journal of the American Medical Association, 272: 114-116 (1994).
  • Steinman, MA., Bero, LA., Chren, M-M., and Landefeld, S. Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents. Annals of Internal Medicine, 145: 284-293 (2006).
  • GE Kennedy and LA Bero. Print Media Coverage of Research on Passive Smoking. Tobacco Control, 8: 254-260 (1999).
  • P Rochon, L Bero, A Bay, J Gold, J Dergal, M Binns, D Streiner, and J Gurwitz. Comparison of Review Articles Published in Peer-Reviewed and Throwaway Journals. Journal of the American Medical Association, 287: 2853-2856 (2002).
  • Montini, T., & Bero, L. Policy Makers’ Perspectives on Tobacco Control Advocates’ Roles in Regulation Development. Tobacco Control, 10: 218-224 (2001).
  • Ober, M., Shohara, R., Rennie, D., Yank, V., & Bero, L.A. The Criticism Management System For The Cochrane Library. Evaluation & The Health Professions, 25(1): 98-115 (2002).
  • Barnes, DE, P Hanauer, J Slade, LA Bero, SA Glantz. Environmental Tobacco Smoke: The Brown and Williamson Documents. Journal of the American Medical Association, 274: 248-253 (1995).
  • Lee, KP., & Bero, LA. Ethics: Increasing Accountability. What Authors, Editors and Reviewers Should do to Improve Peer Review, Nature (An invited article written as part of the journal’s web focus and debate on peer review on June 5) (2006).
  • Misakian, AL; Bero, LA. Publication Bias and Research on Passive Smoking: Comparison of Published and Unpublished Studies. Journal of the American Medical Association, 280(3): 250-3 (1998).
  • Boyd, E., & Bero, L. An Analysis of University Conflict of Interest Committee Decisions. Science and Engineering Ethics, 13: 415-435 (2007).
  • White, J., Parascandola, M., & Bero, L. Tobacco Industry Research and Protection of Human Subjects: A Case Study of R.J. Reynolds. Nicotine and Tobacco Research, 9: 1213-1225 (2007).
  • Lopipero, P., Apollonio, D.E., and Bero, L. Interest Groups, Lobbying and Deception: The Tobacco Industry and Airline Smoking. Political Science Quarterly, 122: 635-656 (Winter 2007-08).
  • Bero, L. Accepting Commercial Sponsorship. British Medical Journal, 319 (11): 653-654 (1999).
  • Rattinger, G and Bero, L. Factors associated with results and conclusions of trials of thiazolidinediones, PLoS One, in press.
  • Boyd, E., Lipton, S., Bero, L. Implementation of Financial Disclosure Policies to Manage Conflicts of Interest. Health Affairs, 23: 206-214 (2004).
  • Finley P, Rens H, Pont J, Gess S, Louie C, Bull S & Bero L. Impact of a Collaborative Pharmacy Practice Model on the Treatment of Depression in Primary Care. American Journal of Health-System Pharmacy, 59: 1518-1526 (2002).
  • Nielsen, JA, Shannon, NJ, Bero, LA, and Moore, KE. Effects of acute and chronic bupropion on locomotor activity and dopaminergic neurons, Pharmacology, Biochemistry and Behavior, 1986; 24: 95-799.
  • Lipton, S., Boyd., E & Bero, LA. Conflicts of Interest in Academic Research: Policies, Processes and Attitudes. Accountability in Research, 11: 83-102 (2004).
  • Hong M, & Bero L. How the Industry Responded to an Influential Study of the Health Effects of Secondhand Smoke. British Medical Journal, 325: 1413-1416 (2002).
  • L.A. Bero and S.A. Glantz. Tobacco Industry Response to a Risk Assessment of Environmental Tobacco Smoke. Tobacco Control, 2: 103-113 (1993).
  • H.L. Lipton, L.A.Bero, J.A. Bird, and S.J. McPhee. The Impact of Clinical Pharmacists'' Consultations on Physicians'' Geriatric Drug Prescribing: A Randomized Controlled Trial. Med Care, 30: 646-658 (1992).
  • Mangurian, C. V. & Bero, L. A. Lessons Learned from the Tobacco Industry’s Efforts to Prevent the Passage of a Workplace Smoking Regulation. American Journal of Public Health, 90(12): 1926-1929 (2000).
  • H.L. Lipton, J.A. Bird, L.A. Bero, and S.J. McPhee. Assessing the Appropriateness of Physician Prescribing for Geriatric Outpatients: Developing and Testing of an Instrument. J. Pharm. Technol, 9: 107-113 (1992).
  • Bero, LA. Disclosure Policies for Gifts from Industry to Academic Faculty [editorial; comment]. Journal of the American Medical Association, 279(13):1031-2 (1998).
  • Bero, LA. Tobacco Industry Manipulation of Research. Public Health Reports, 120: 200-208 (2005).
  • Bero, L, and A. Jadad. How Consumers and Policy Makers can Use Systematic Reviews for Decision-Making. Annals of Internal Medicine, 127:37-42 (1997).
  • Lopipero, P., and Bero, L. Tobacco Interests or the Public Interest: Twenty Years of Industry Strategies to Undermine Airline Smoking Restrictions. Tobacco Control, 15: 323-332 (2006).
  • Bero, L.A. Evaluating Systematic Reviews and Meta-Analyses. Journal of Law & Policy, 14: 569-593 (2006).
B